US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

43.40

-0.0545-0.13%

Post-market: 43.34-0.0610-0.14%19:30 EDT

Volume:2K

Turnover:104.72K

Market Cap:120.53M

PE:- -

High:43.93

Open:43.78

Low:43.20

Close:43.46

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:1.11

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

LivaNova to Discuss Third-Quarter 2026 Results on Conference Call

LivaNova to Announce Third-Quarter 2026 Results

THOMSON REUTERS

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

MT Newswires Live

Travere Therapeutics receives notice of allowance for FILSPARI patent

Travere Therapeutics - Receives USPTO Notice of Allowance for Filspari Patent in FSGS

Travere Therapeutics, - Receives Uspto Notice of Allowance for Filspari Patent in Fsgs

THOMSON REUTERS

Travere Gets USPTO Notice of Allowance for Filspari Use in FSGS Patent Application

Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II

New precision medicine venture gives Syngenis added firepower

The West Australian

Novo Nordisk CEO Signals Deal-Making Ambitions to Strengthen Drug Pipeline

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Travere Therapeutics CEO Dube to step down

Travere Therapeutics Names Bradley Campbell CEO, Effective Dec. 1, 2026

Travere Therapeutics, - Appoints Bradley L. Campbell as President and CEO Effective December 1, 2026

THOMSON REUTERS

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

Ultragenyx price target raised to $35 from $32 at Barclays

Innovative Drug Sector Heats Up: Spotlight on Pure-Play R&D Developers

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

Electra Therapeutics indicated to open at $20, IPO priced at $15

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/LFSC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":43.401,"timestamp":1790971200000,"preClose":43.4555,"halted":0,"volume":2400,"hourTrading":{"tag":"盘后","latestPrice":43.34,"preClose":43.401,"latestTime":"19:30 EDT","volume":10,"amount":433.284,"timestamp":1790983803387,"change":-0.061,"changeRate":-0.001405,"amplitude":0},"delay":0,"changeRate":-0.001254156550954363,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Market Closed","change":-0.0545,"latestTime":"10-02 16:00:00 EDT","open":43.775,"high":43.93,"low":43.195,"amount":104721.6336,"amplitude":0.016914,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":43.4555,"sharesOutstanding":2657035,"nav":43.44,"aum":120634400.4,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.34,"preClose":43.401,"latestTime":"19:30 EDT","volume":10,"amount":433.284,"timestamp":1790983803387,"change":-0.061,"changeRate":-0.001405,"amplitude":0},"volumeRatio":1.1111110185185262},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1111110185185262,"shares":2777035,"dividePrice":0,"high":43.93,"amplitude":0.016914,"preClose":43.4555,"low":43.195,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":43.401,"eps":0,"divideRate":0,"volume":2400,"delay":0,"ttmEps":0,"open":43.775,"prevYearClose":36.6147,"prevWeekClose":44.4638,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":44.4638,"twentyDayClose":46.1466,"sixtyDayClose":47.375},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","BK4585","MRNX","IDNA","XLVX","IBB","MEDI","BBP","RSPH","LABU","IYH","TBXU","LFSC","PSCH","BMED","TECB","BK4139","IEIH","GNMX","MESO","BK4588","GDOC","SYNB","MRNY","PINK","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669864994","title":"LivaNova to Discuss Third-Quarter 2026 Results on Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2669864994","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669864994?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:02","pubTimestamp":1790168546,"startTime":"0","endTime":"0","summary":"LivaNova to discuss third-quarter 2026 results on conference callLivaNova will release third-quarter 2026 results ahead of a conference call on Nov. 4, 2026.Results call scheduled for 1 p.m. GMT on No","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL8QDqLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIVN","BK4082","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD","LFSC","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486182","title":"LivaNova to Announce Third-Quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486182?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168406,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA55JRCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171402.SGD","LU2065171311.SGD","BK4082","LU2065170008.USD","LU2065169927.USD","LIVN","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669848334","title":"Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI","url":"https://stock-news.laohu8.com/highlight/detail?id=2669848334","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669848334?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:49","pubTimestamp":1790164165,"startTime":"0","endTime":"0","summary":"Travere Therapeutics  said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for certain methods of using FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease.The company said it expects to receive the patent, which is expected to provide US patent coverage for certain methods of using FILSPARI in the disease into October 2037, after paying the issue fee and completing standard USPTO post-allowance processing.Travere said it expects to submit the patent for listing in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations after receiving the grant.Shares of the company were down 1.3% in Wednesday's premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["USRD","BK4539","BK4007","LENZ","LFSC","BK4139","FFTY","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669448832","title":"Travere Therapeutics receives notice of allowance for FILSPARI patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2669448832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669448832?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:10","pubTimestamp":1790161811,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application N...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-receives-notice-of-allowance-for-filspari-patent-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-receives-notice-of-allowance-for-filspari-patent-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","FFTY","BK4139","TVTX","BK4007","USRD","LFSC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669002651","title":"Travere Therapeutics - Receives USPTO Notice of Allowance for Filspari Patent in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2669002651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669002651?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:05","pubTimestamp":1790161518,"startTime":"0","endTime":"0","summary":"BRIEF-Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGSSept 23 (Reuters)-Travere Therapeutics, Inc.TVTX.O:TRAVERE THERAPEUTICS, - RECEIVES USPTO NOTICE OF ALLOWANCE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669004601","title":"Travere Therapeutics, - Receives Uspto Notice of Allowance for Filspari Patent in Fsgs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669004601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669004601?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:04","pubTimestamp":1790161465,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100187","title":"Travere Gets USPTO Notice of Allowance for Filspari Use in FSGS Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100187","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100187?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:01","pubTimestamp":1790161289,"startTime":"0","endTime":"0","summary":"Travere gets USPTO notice of allowance for FILSPARI use in FSGS patent applicationTravere received a USPTO notice of allowance for a U.S. patent application covering methods of using FILSPARI (sparsen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDLM52zl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669108132","title":"Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II","url":"https://stock-news.laohu8.com/highlight/detail?id=2669108132","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669108132?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:24","pubTimestamp":1790144664,"startTime":"0","endTime":"0","summary":"An update from Sensorion SAS ( ($FR:ALSEN) ) is now available. Sensorion has sharpened its strategic focus on SENS-601, a single-vector AAV gene th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","CNCR","LFSC","IBBQ","BK4585","SENS","GNOM","FBT","BK4082","SYNB","IBB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["IBB","IDNA","IMLC.AU","GNOM","IIGF.AU","BBOZ.AU","STW.AU","MEDX","GIVE.AU","SLF.AU","E200.AU","OZR.AU","HTEC","XT","BEAR.AU","FDIF","JDOC","OZF.AU","XKO.AU","BK4585","DACE.AU","VAP.AU","ZYAU.AU","EES","HELX","BMED","QFN.AU","IISV.AU","ADHD","TMAT","BK4588","IOZ.AU","LFSC","EIGA.AU","VAS.AU","SYNB","GEAR.AU","QRE.AU","WDNA","GNMX","XJO.AU","PBE","XAO.AU","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168643565","title":"Novo Nordisk CEO Signals Deal-Making Ambitions to Strengthen Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1168643565","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168643565?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:20","pubTimestamp":1790068822,"startTime":"0","endTime":"0","summary":"Novo Nordisk's chief executive has openly floated the possibility of acquisitions as the company navigates an increasingly crowded weight-loss drug market. Mike Doustdar, who leads the Danish...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","XMMO","LFSC","BK4588","CALF","MYLD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669198404","title":"Travere Therapeutics Announces Planned Chief Executive Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2669198404","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669198404?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:18","pubTimestamp":1790021936,"startTime":"0","endTime":"0","summary":"BRIEF-Travere Therapeutics Announces Planned Chief Executive Officer TransitionSept 22 (Reuters)-Travere Therapeutics, Inc.TVTX.O:TRAVERE THERAPEUTICS ANNOUNCES PLANNED CHIEF EXECUTIVE OFFICER TRANSIT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA34RQPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669198265","title":"Travere Therapeutics CEO Dube to step down","url":"https://stock-news.laohu8.com/highlight/detail?id=2669198265","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669198265?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:10","pubTimestamp":1790021439,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) announced that Eric Dube, Ph.D., has made the decision to step down as president and chief executive officer to “focus ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-ceo-dube-to-step-down-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-ceo-dube-to-step-down-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVTX","BK4539","BK4139","BK4007","LFSC","FFTY","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669198991","title":"Travere Therapeutics Names Bradley Campbell CEO, Effective Dec. 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669198991","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669198991?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:05","pubTimestamp":1790021131,"startTime":"0","endTime":"0","summary":"Travere Therapeutics names Bradley Campbell CEO, effective Dec. 1, 2026Travere Therapeutics named Bradley L. Campbell as president, CEO, board member, effective Dec. 1, 2026.Outgoing CEO Eric Dube wil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL9lVyFz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","IE00BFXG1179.USD","LU0237698245.USD","LFSC","IE00B2B36J28.USD","LU2133065610.SGD","LU1291159041.SGD","LU2242646821.SGD","LU1236620834.HKD","LU0096364046.USD","IE00BJJMRZ35.SGD","IHE","BK4588","LU1261432733.SGD","LU1670711040.USD","LU2125154778.USD","IE0002141913.USD","IE0002270589.USD","BK4585","IE00B7SZLL34.SGD","LU0114720955.EUR","BMY","FTXH","LU0321505439.SGD","BK4581","LU0882574055.USD","LU1032466523.USD","IE0009355771.USD","LU1571399168.USD","LU1983299246.USD","LU1585245621.USD","LU0456855351.SGD","LU1670710661.SGD","LU0321505868.SGD","BMRN","LU2596442595.SGD","LU2360032135.SGD","LU2125154935.USD","LU1093756168.USD","LU1868837136.USD","LU1868837300.USD","LU1989771016.USD","LU1868836757.USD","LU1430594728.SGD","BK4566","TVTX","LU0267386448.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0225284248.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669966198","title":"Travere Therapeutics, - Appoints Bradley L. Campbell as President and CEO Effective December 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669966198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669966198?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:05","pubTimestamp":1790021100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA34RQPB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316610","title":"InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316610","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316610?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:00","pubTimestamp":1789995600,"startTime":"0","endTime":"0","summary":"- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365503/0/en/inspiremd-announces-amendments-to-certain-series-j-and-series-k-warrants-providing-potential-gross-proceeds-of-up-to-11-million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","MRNY","LFSC","PSCH","IEIH","SYNB","MEDI","GNMX","RSPH","MRNX","PINK","NSPR","BMED","BK4585","BBP","BK4588","IBB","NVIB","TBXU","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","PINK","BK4139","PSCH","MRNX","MRNY","IBB","TECB","RSPH","BK4588","GDOC","SYNB","IEIH","BMED","GNMX","MEDI","BK4585","IDNA","BBP","IYH","TBXU","FRTY","RARE","LABU","NVIB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181721651","title":"Innovative Drug Sector Heats Up: Spotlight on Pure-Play R&D Developers","url":"https://stock-news.laohu8.com/highlight/detail?id=1181721651","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181721651?lang=en_us&edition=fundamental","pubTime":"2026-09-21 14:01","pubTimestamp":1789970464,"startTime":"0","endTime":"0","summary":"A bullish MACD crossover signal has emerged, indicating strong upward momentum for select pharmaceutical stocks. This technical indicator, often seen as a precursor to sustained gains, has caught the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","SBIO","GDOC","BK4585","BK4588","BK1161","BBP","LFSC","MEDX","GSKH","APXH","IBBQ","BK1574","159992","BIOY","06978","XLVI","LNGR","IBB","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","MRNX","TECB","MEDI","GDOC","GNMX","LABU","LFSC","IYH","MRNY","BK4007","BK4588","NVIB","FRTY","IDNA","XLVX","BBP","PSCH","IEIH","AMRX","SYNB","RSPH","PINK","IBB","BK4585","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668892453","title":"Electra Therapeutics indicated to open at $20, IPO priced at $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2668892453","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668892453?lang=en_us&edition=fundamental","pubTime":"2026-09-18 22:55","pubTimestamp":1789743321,"startTime":"0","endTime":"0","summary":"Electra Therapeutics (ETRA), a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/electra-therapeutics-indicated-to-open-at-20-ipo-priced-at-15-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/electra-therapeutics-indicated-to-open-at-20-ipo-priced-at-15-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XT","HELX","BMED","IDNA","MEDX","LFSC","BK4585","BK4588","REDS","GDOC","HTEC","IBB","IPOS","FRHC","PBE","GNOM","FDIF","SYNB","JDOC","ETRA","TMAT","BK4127","GNMX","KCE","WDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}